Voyager reports Q3 2026 results, cash runway into Q2 2028
The company said VY7523 tau PET data remain on track for Q4 2026 and VY1706 dosing should begin within months, pending enrollment.
SEC filing
2 stories
The company said VY7523 tau PET data remain on track for Q4 2026 and VY1706 dosing should begin within months, pending enrollment.
SEC filing
Voyager's board elevated Swartz to president effective October 20, 2026, with plans for her to become CEO after early safety data from a VY1706 Alzheimer's trial arrive.
SEC filing